Nagy Attila, Májer Réka, Boczán Judit, Sipka Sándor, Szabó Attila, Enyedi Enikő Edit, Tatai Ottó, Fagyas Miklós, Papp Zoltán, Csiba László, Tóth Attila
Department of Health Informatics, Institute of Health Sciences, Faculty of Health Sciences, University of Debrecen, 4032 Debrecen, Hungary.
Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Biomedicines. 2023 Dec 15;11(12):3323. doi: 10.3390/biomedicines11123323.
Angiotensin-converting enzyme (ACE) inhibitors are the primarily chosen drugs to treat various cardiovascular diseases, such as hypertension. Although the most recent guidelines do not differentiate among the various ACE inhibitory drugs, there are substantial pharmacological differences.
Here, we tested if lipophilicity affects the efficacy of ACE inhibitory drugs when used as the first therapy in newly identified hypertensives in a prospective study.
We tested the differences in the cardiovascular efficacy of the hydrophilic lisinopril (8.3 ± 3.0 mg/day) and the lipophilic enalapril (5.5 ± 2.3 mg/day) ( = 59 patients). The cardiovascular parameters were determined using sonography (flow-mediated dilation (FMD) in the brachial artery, intima-media thickness of the carotid artery), 24 h ambulatory blood pressure monitoring (peripheral arterial blood pressure), and arteriography (aortic blood pressure, augmentation index, and pulse wave velocity) before and after the initiation of ACE inhibitor therapy.
Both enalapril and lisinopril decreased blood pressure. However, lisinopril failed to improve arterial endothelial function (lack of effects on FMD) when compared to enalapril. Enalapril-mediated improved arterial endothelial function (FMD) positively correlated with its blood-pressure-lowering effect. In contrast, there was no correlation between the decrease in systolic blood pressure and FMD in the case of lisinopril treatment.
The blood-pressure-lowering effects of ACE inhibitor drugs are independent of their lipophilicity. In contrast, the effects of ACE inhibition on arterial endothelial function are associated with lipophilicity: the hydrophilic lisinopril was unable to improve, while the lipophilic enalapril significantly improved endothelial function. Moreover, the effects on blood pressure and endothelial function did not correlate in lisinopril-treated patients, suggesting divergent mechanisms in the regulation of blood pressure and endothelial function upon ACE inhibitory treatment.
血管紧张素转换酶(ACE)抑制剂是治疗各种心血管疾病(如高血压)的首选药物。尽管最新指南并未区分各种ACE抑制药物,但它们在药理学上存在显著差异。
在此,我们通过一项前瞻性研究,测试了亲脂性是否会影响ACE抑制药物作为新确诊高血压患者的初始治疗药物时的疗效。
我们测试了亲水性赖诺普利(8.3±3.0毫克/天)和亲脂性依那普利(5.5±2.3毫克/天)(n = 59例患者)在心血管疗效上的差异。在开始ACE抑制剂治疗前后,使用超声检查(肱动脉血流介导的舒张功能(FMD)、颈动脉内膜中层厚度)、24小时动态血压监测(外周动脉血压)和血管造影(主动脉血压、增强指数和脉搏波速度)来测定心血管参数。
依那普利和赖诺普利均能降低血压。然而,与依那普利相比,赖诺普利未能改善动脉内皮功能(对FMD无影响)。依那普利介导的动脉内皮功能改善(FMD)与其降压效果呈正相关。相比之下,在赖诺普利治疗的情况下,收缩压降低与FMD之间无相关性。
ACE抑制剂药物的降压效果与其亲脂性无关。相反,ACE抑制对动脉内皮功能的影响与亲脂性有关:亲水性赖诺普利无法改善内皮功能,而亲脂性依那普利能显著改善内皮功能。此外,在赖诺普利治疗的患者中,血压和内皮功能的影响不相关,这表明在ACE抑制治疗中,血压调节和内皮功能调节的机制不同。